Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
Bioconjugate Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Brain
tumors,
particularly
glioblastomas,
represent
the
most
complicated
cancers
to
treat
and
manage
due
their
highly
invasive
nature
protective
barriers
of
brain,
including
blood-brain
barrier
(BBB).
The
efficacy
currently
available
treatments,
viz.,
radiotherapy,
chemotherapy,
immunotherapy,
are
frequently
limited
by
major
side
effects,
drug
resistance,
restricted
penetration
into
brain.
Lipid
nanoparticles
(LNPs)
have
emerged
as
a
promising
targeted
delivery
system
for
brain
tumors.
nanocarriers
gained
tremendous
attention
tumor
therapeutics
multiple
encapsulation
abilities,
controlled
release,
better
biocompatibility,
ability
cross
BBB.
Herein,
detailed
analysis
design,
mechanisms,
therapeutic
benefits
LNPs
in
treatment
is
discussed.
Moreover,
we
also
discuss
safety
issues
clinical
developments
current
future
challenges.
Further,
focused
on
transformation
therapy
eliminating
effects
engineering
overcome
related
biological
barriers,
which
provide
personalized,
affordable,
low-risk
options.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 524 - 524
Published: Jan. 15, 2025
Background:
Cerebral
intra-arterial
chemotherapy
(CIAC)
has
been
demonstrated
to
achieve
tumoricidal
concentrations
in
cerebral
tumour
cells
that
are
otherwise
unachievable
due
the
presence
of
blood–brain
barrier.
In
this
study,
we
sought
analyze
safety
CIAC
a
cohort
patients
treated
at
Centre
intégré
universitaire
de
santé
et
services
sociaux
l’Estrie—Centre
hospitalier
Sherbrooke
(CIUSSS-CHUS).
Methods:
Treatments
consisted
monthly
CIAC.
A
neurological
examination
and
neuroimaging
study
(MRI)
were
performed
before
every
treatment.
The
files
enrolled
our
programme
reviewed.
Adverse
events
analyzed
categorized.
Results:
Overall,
2991
procedures
642
patients.
Pathologies
as
follows:
malignant
gliomas
(68.7%),
metastasis
(17.6%),
lymphomas
(13.7%).
Perfusion
vessels
80%
internal
carotid
artery
20%
vertebral
artery.
chemotherapeutic
agents
used
carboplatin
(86.4%),
methotrexate
(28.5%),
melphalan
(28.6%),
liposomal
doxorubicin
(2.8%).
Osmotic
barrier
disruption
(BBBD)
was
induced
30.5%
treatments.
Symptomatic
vascular
adverse
occurred
during
27
(0.9%)
26
(4%).
Namely,
23
strokes,
one
occlusion
(responsible
for
strokes),
two
intratumoral
subdural
hemorrhage.
absolute
risk
stroke
1.3%
0.5%
with
or
without
BBBD,
respectively.
use
significantly
increased
stroke.
Drug
infusion-related
seizures
2.5%
patients;
83.8%
associated
16.2%
carboplatin.
Conclusions:
is
safe
procedure
0.9%
overall
rate
symptomatic
complications
(stroke,
occlusion,
hemorrhage
bleeding—n
=
27/2991)
on
treatment
basis,
mainly
consisting
strokes
(85%,
n
23),
modified
NIH
Stroke
Scale
score
4.1
±
3.3.
Biomacromolecules,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 11, 2024
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
with
poor
prognosis
and
limited
treatment
options.
Drug
delivery
by
stimuli-responsive
nanocarriers
holds
great
promise
for
improving
the
modalities
of
GBM.
At
beginning
review,
we
highlighted
stimuli-active
polymeric
carrying
therapies
that
potentially
boost
anti-GBM
responses
employing
endogenous
(pH,
redox,
hypoxia,
enzyme)
or
exogenous
stimuli
(light,
ultrasonic,
magnetic,
temperature,
radiation)
as
triggers
controlled
drug
release
mainly
via
hydrophobic/hydrophilic
transition,
degradability,
ionizability,
etc.
Modifying
these
target
ligands
further
enhanced
their
capacity
to
traverse
blood-brain
barrier
(BBB)
preferentially
accumulate
in
glioma
cells.
These
unique
features
lead
more
effective
cancer
minimal
adverse
reactions
superior
therapeutic
outcomes.
Finally,
review
summarizes
existing
difficulties
future
prospects
treating
Overall,
this
offers
theoretical
guidelines
developing
intelligent
versatile
facilitate
precise
GBM
clinical
settings.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 22, 2025
Cerebrovascular
imaging
is
essential
for
the
diagnosis,
treatment,
and
prognosis
of
cerebrovascular
disease,
including
stroke,
aneurysms,
vascular
malformations.
Conventional
techniques
such
as
MRI,
CT,
DSA
ultrasound
have
their
own
strengths
limitations,
particularly
in
terms
resolution,
contrast
safety.
Recent
advances
nanotechnology
offer
new
opportunities
improved
imaging.
Nanomaterials,
metallic
nanoparticles,
magnetic
quantum
dots,
carbon-based
nanomaterials,
polymer
show
great
potential
due
to
unique
physical,
chemical,
biological
properties.
This
review
summarizes
recent
advanced
nanomaterials
applications
various
techniques,
discusses
challenges
future
research
directions.
The
aim
provide
valuable
insights
researchers
facilitate
development
clinical
application
these
innovative
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 245 - 245
Published: Feb. 13, 2025
Recent
advancements
in
nanotechnology
have
revolutionized
cancer
therapy-one
of
the
most
pressing
global
health
challenges
and
a
leading
cause
death-through
development
liposomes
(L),
lipid-based
nanovesicles
known
for
their
biocompatibility
ability
to
encapsulate
both
hydrophilic
lipophilic
drugs.
More
recent
innovations
led
creation
stimuli-responsive
L
that
release
payloads
response
specific
endogenous
or
exogenous
triggers.
Dual-
multi-responsive
L,
which
react
multiple
stimuli,
offer
even
greater
precision,
improving
therapeutic
outcomes
while
reducing
systemic
toxicity.
Additionally,
these
smart
can
adjust
physicochemical
properties
morphology
enable
site-specific
targeting
controlled
drug
release,
enhancing
treatment
efficacy
minimizing
adverse
effects.
This
review
explores
latest
liposomal
nanocarriers,
as
well
dual-
integrate
internal
external
triggers,
with
focus
on
design
strategies,
mechanisms,
applications
therapy.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(4), P. 701 - 701
Published: Feb. 19, 2025
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
that
has
bleak
outlook
despite
existing
treatments
such
as
surgery,
radiation,
and
chemotherapy.
The
utilization
of
nanoparticles
for
drug
delivery
presents
promising
method
by
which
to
improve
the
effectiveness
treatment
while
reducing
harmful
effects
on
entire
body.
This
review
examines
application
in
GBM,
focusing
different
types
nanoparticles,
including
lipid-based,
polymeric,
metallic,
those
under
development.
Every
variety
analyzed
its
distinct
characteristics
therapeutic
capacity.
Lipid-based
liposomes
solid
lipid
enhance
transport
medicines
are
not
soluble
water
have
shown
considerable
potential
preclinical
investigations.
Polymeric
benefits
terms
controlled
release
targeted
distribution,
whereas
metallic
both
therapy
imaging.
In
current
we
would
like
emphasize
ways
medicine
delivery,
specifically
enhancing
penetration
blood-brain
barrier
(BBB),
targeting
tumors,
enabling
release.
Additionally,
also
discuss
clinical
discoveries,
highlighting
achievements
obstacles
process
converting
these
technologies
into
effective
GBM.
study
offers
thorough
examination
present
status
prospects
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: March 6, 2025
Synthetic
biology
and
nanotechnology
fusion
represent
a
transformative
approach
promoting
fundamental
clinical
biomedical
science
development.
In
SynBioNanoDesign,
biological
systems
are
reimagined
as
dynamic
programmable
materials
to
yield
engineered
nanomaterials
with
emerging
specific
functionalities.
This
review
elucidates
comprehensive
examination
of
synthetic
biology's
pivotal
role
in
advancing
for
targeted
drug
delivery
systems.
It
begins
exploring
the
synergy
between
nanotechnology,
then
highlights
current
landscape
applications.
Subsequently,
discusses
design
novel
informed
by
principles,
focusing
on
expounding
tools
potential
developing
advanced
nanomaterials.
Afterward,
research
advances
innovative
through
were
systematically
summarized,
emphasizing
integration
genetic
circuitry
program
nanomaterial
responses.
Furthermore,
challenges,
weaknesses
opportunities,
prospective
directions,
ethical
societal
implications
SynBioNanoDesign
elucidated.
Finally,
summarizes
impact
that
may
have
drug-delivery
technologies
future.
Small,
Journal Year:
2025,
Volume and Issue:
21(9)
Published: Jan. 22, 2025
Abstract
Nanomaterials
with
unparalleled
physical
and
chemical
attributes
have
become
a
cornerstone
in
the
field
of
nanomedicine
delivery.
These
materials
can
be
engineered
into
various
functionalized
nanocarriers,
which
focus
research.
Stimulus‐responsive
nanodrug
delivery
systems
(SRDDS)
stand
out
as
sophisticated
class
nanocarriers
that
release
drugs
response
to
environmental
cues.
Due
complex
pathogenesis
multifaceted
pathological
environment
nervous
system,
developing
accurate
effective
drug
therapy
low
side‐effects
is
formidable
task.
In
recent
years,
SRDDS
been
widely
used
treatment
neurological
diseases.
By
customizing
align
specific
microenvironment
system
tissues
or
external
stimulation,
efficacy
enhanced.
This
review
provides
an
in‐depth
look
at
characteristics
diseases
highlights
case
studies
tailored
treat
these
disorders
based
on
unique
stimulation
criteria
triggers.
Additionally,
this
comprehensive
overview
progress
future
prospects
technology
diseases,
providing
valuable
guidance
for
its
transition
from
fundamental
research
clinical
application.
